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background:  The first-in-class Absorb (Abbott Vascular, Santa Clara, CA) bioresorbable scaffold (BRS) is eluting everolimus, but 
a number of other scaffolds are in development with sirolimus as the antirestenotic agent. In this study, we set out to correlate the 
pharmacokinetic data with antirestenotic efficacy of a novel sirolimus-eluting BRS (Amaranth Medical, Mountain View, CA) in comparison to 
the benchmark Absorb device.
methods:  Twenty-four coronary arteries of 8 swine received sirolimus-eluting BRS (n=16) or BVS (Absorb, n=8) were terminated for 
the histopathology following imaging with angiography and optical coherence tomography (OCT) at 28 and 90 days. Another 53 BRS 
underwent tissue (n=32,1, 7, 28, and 90days), blood (n=9, 11 time points within 7 days) and organ pharmacokinetics (n=12 at 28, 90, and 
180 days). Histopathology analysis included fibrin deposition (0-none to 3=heavy) and neointimal maturity grade (0=immature to 3=mature) 
based on hematoxylin and eosin (H&E) and elastin trichrome staining.
results:  BRS showed a similar neointimal area compared to BVS at 28 days and 90 days (1.49±0.34 mm2 vs. 1.77±0.38 mm2, p=0.27 
and 2.11±0.93mm2 vs. 1.78±0.26 mm2, p=0.37, respectively). Histopathology revealed favorable trends in healing form 28 to 90 days 
(neointimal maturity 2.0 to 3.0; fibrin deposition from 1.75 to 0.19.) Majority of sirolimus was eluted by 90days (% drug released: 75% and 
89.5% at 28 days and 90days, respectively) and the tissue drug concentration declined from 24.33 ug/g at 1day to 15.95 ug/g at 90 days. 
Average peak of systemic (blood) sirolimus concentration was 3 ng/ml (>200 ng/ml is considered safe after systemic administration). Organ 
sirolimus exposure was not quantifiable at any time point.
Conclusion:  The novel sirolimus-eluting BRS showed favorable effect on neointimal formation and healing up to 90 days, in tune with the 
sirolimus release by which the local arterial tissue concentration is adequate, but only ~10% of sirolimus is still present on the scaffold, and 
the systemic exposure is negligible.
